Navigation Links
Luminex Corporation Reports First Quarter 2012 Results
Date:4/30/2012

AUSTIN, Texas, April 30, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the first quarter ended March 31, 2012.  Financial and operating highlights include the following:

  • Consolidated first quarter revenue was $48.7 million, a 13 percent increase over the first quarter of 2011
  • First quarter assay revenue was $17.3 million, a 80 percent increase over the first quarter of 2011
  • First quarter shipments of 206 multiplexing analyzers that included 55 MAGPIX® systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 8,884, up 12 percent from a year ago
  • Consolidated gross profit margin was 69 percent for the first quarter of 2012
  • Operating expenses for the first quarter of 2012 were $28.2 million, an increase of $5.7 million over the first quarter of 2011. $2.1 million of this increase can be attributed to Luminex Madison, formerly known as EraGen Biosciences, that was acquired on June 27, 2011
  • Operating income for the first quarter of 2012 was $5.6 million compared with operating income of $8.3 million for the same period last year
  • Extended a global sales and distribution agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO) under which Luminex has granted Bio-Rad global sales and distribution rights for Luminex's MAGPIX multiplexing analyzer and extended the strategic partnership agreement until 2023
  • Received CE marking for the newborn screening assay, xMAP® NeoPlex4™, and a fully automated instrument, the NeoPlex System, in April
  • (Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

     REVENUE SUMMARY
    (in thousands, except p
    '/>"/>

    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012
    2. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
    3. Luminex Corporation Vice President of Biodefense to Speak at DTRAS 2011 CBD S&T Conference
    4. Luminex Corporation Reports Third Quarter 2011 Results
    5. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
    6. Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
    7. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
    8. Luminex Corporation to Present at Upcoming Investment Conferences In September
    9. Luminex Corporation Reports Second Quarter 2011 Results
    10. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
    11. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
    (Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
    ... New data show the,investigational drug tetrabenazine maintained ... up to 80 weeks in those,patients who ... data suggest that tetrabenazine can be used ... use., "These findings demonstrate the potential benefit ...
    ... Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical company, ... respected scientific,journal 'Synapse'* on its Phase II NMDA ... a potential treatment for neuropathic,pain. The independent study ... with CNS 5161. , In the study reported ...
    Cached Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
    (Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
    (Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
    (Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
    (Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
    (Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
    Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
    ... and SANTA CLARA, Calif., Jan. 13 Gulf ... care facilities in,the nation, announced it will be ... ultrasound platforms from Eklin Medical Systems.,GCVS currently uses ... and Communications System) as part of the,facility,s Eklin ...
    ... respiratory distress, researchers say; company says product is safe ... cold remedy Vicks VapoRub may cause airway inflammation that ... study says. , Doctors at Wake Forest University started ... developed severe respiratory distress after the salve had been ...
    ... Interventions Incorporated into, First-of-its-Kind Study ... Jan. 13 /PRNewswire/ - MEMOTEXT announced today that ... will conduct a clinical trial on patient adherence ... technology developed by MEMOTEXT. The clinical trial, titled ...
    ... KENNEBUNK, Maine, Jan. 13 The new year brings ... its steadfast commitment to community programs. This month, the ... brings everyday Americans and local communities together with Tom,s ... care for families in need. Over the past four ...
    ... new turn. Now you can see the ... Early on Christmas morning, CNN ... "What is Telemedicine?" demonstrating how telemedicine is ... healthcare to patients at six area Walmart ...
    ... Synergy Connect(TM) links health plan, physicians and ... Fla., Jan. 13 Health Integrated, a ... helping people with chronic illnesses get the ... communities. Health Integrated,s groundbreaking Synergy Connect(TM) service ...
    Cached Medicine News:Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 2Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 4Health News:Tom's of Maine Invites Everyone to Start the New Year by Helping Families in Need 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 3Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3
    Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
    BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
    Streptavidin MicroBeads are used for the indirect magnetic labeling and separation of cells, subcellular material, or bacteria labeled with a biotinylated primary antibody or ligand....
    Malaria antibody EIA 480 test kit...
    Medicine Products: